Merus Granted FDA Fast Track Designation of Zenocutuzumab for the Treatment of Patients with Neuregulin 1 Fusion Cancers

NEXT STORY
AnaptysBio to Present at the 39th Annual J.P. Morgan Healthcare Conference
PREV STORY
Coherus BioSciences Appoints Alan Mendelson and Mark Stolper to Board of Directors
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Stereotaxis Launches Vmotion Suite of Automation Features in U.S. Following FDA Clearance

ST. LOUIS, Sept. 23, 2015 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NASDAQ:STXS), a global leader ...

author_avatar
NASDAQ Market News

Publication Identifies Cyclin E as Key Resistance Pathway to Breast Cancer Treated by CDK4/6 Inhibitors and Thereby Amenable to Treatment by CYC065 CDK2/9 Inhibitor

author_avatar
NASDAQ Market News

VBI Vaccines Presents New Data Supporting its Glioblastoma Immunotherapy Program at the Keystone Symposia Cancer Vaccines Conference

CAMBRIDGE, Mass., March 07, 2016 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq:VBIV) (“VBI”) today ...

author_avatar
NASDAQ Market News